Genomic sites of topoisomerase II activity determined by comparing DNA breakage enhanced by three distinct poisons

Journal of Molecular Biology

Volumn 285, Issue 2, 1999, Pages 545-554

  Borgnetto, M Evelina ^a   Tinelli, Stella ^a   Carminati, Laura ^a   Capranico, Giovanni ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chromatin structure; DNA cleavage; DNA protein interaction; Heterochromatin; Topoisomerase II

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CLEROCIDIN; DNA FRAGMENT; DNA TOPOISOMERASE (ATP HYDROLYSING); POISON; SATELLITE DNA; TENIPOSIDE; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ARTICLE; CENTROMERE; CHROMATIN STRUCTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA CLEAVAGE; DROSOPHILA MELANOGASTER; ENZYME ACTIVITY; GENE SEQUENCE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PULSED FIELD GEL ELECTROPHORESIS; START CODON;

ANIMALIA; ARACHNIDA; DROSOPHILA MELANOGASTER; HEXAPODA; MELANOGASTER;

EID: 0033555774     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1998.2330     Document Type: Article

References (46)

1. Adachi Y., Käs E., Laemmli U. K. Preferential, cooperative binding of DNA topoisomerase II to scaffold-associated regions. EMBO J. 8:1989;3997-4006.
2. Adachi Y., Luke M., Laemmli U. K. Chromosome assembly in vitro: topoisomerase II is required for condensation. Cell. 64:1991;137-148.
3. Binaschi M., Zagotto G., Palumbo M., Zunino F., Farinosi R., Capranico G. Irreversible and reversible topoisomerase II DNA cleavage stimulated by clerocidin: sequence specificity and structural drug determinants. Cancer Res. 57:1997;1710-1716.
4. Borde V., Duguet M. In vivo topoisomerase II cleavage sites in the ribosomal DNA of Physarum polycephalum. Biochemistry. 35:1996;5787-5795.
5. Borgnetto M. E., Zunino F., Tinelli S., Kas E., Capranico G. Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility. Cancer Res. 56:1996;1855-1862.
6. Capranico G., Kohn K. W., Pommier Y. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucl. Acids Res. 18:1990;6611-6619.
7. Capranico G., Supino R., Binaschi M., Capolongo L., Grandi M., Suarato A., Zunino F. Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance. Mol. Pharmacol. 45:1994;908-915.
8. Capranico G., Binaschi M., Borgnetto M. E., Zunino F., Palumbo M. A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons. Trends Pharmacol. Sci. 18:1997;303-346.
9. Cullinan E. B., Beerman T. A. A study of drug-induced topoisomerase II-mediated DNA lesions on episomal chromatin. J. Biol. Chem. 264:1989;16268-16275.
10. Downes C. S., Mullinger A. M., Johnson R. T. Inhibitors of DNA topoisomerase II prevent chromatid separation in mammalian cells but do not prevent exit from mitosis. Proc. Natl Acad. Sci. USA. 88:1991;8895-8899.
11. Ebert S. N., Shtrom S. S., Muller M. T. Topoisomerase II cleavage of herpes simplex virus type 1 DNA in vivo is replication dependent. J. Virol. 64:1990;4059-4066.
12. Ekwall K., Olsson T., Turner B. M., Cranston G., Allshire R. C. Transient inhibition of histone deacetylation alters the structural and functional imprint at fission yeast centromeres. Cell. 91:1997;1021-1032.
13. Fan Y., Weinstein J. N., Kohn K. W., Shi L. M., Pommier Y. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. J. Med. Chem. 41:1998;2216-2226.
14. Freudenreich C. H., Kreuzer K. N. Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex. Proc. Natl Acad. Sci. USA. 91:1994;11007-11011.
15. Froelich-Ammon S. J., Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem. 270:1995;21429-21432.
16. Gasser S. M., Laemmli U. K. The organisation of chromatin loops: characterization of a scaffold attachment site. EMBO J. 5:1986;511-518.
17. Gromova I. I., Nielsen O. F., Razin S. V. Long-range fragmentation of the eukaryotic genome by exogenous and endogenous nucleases proceeds in a specific fashion via preferential DNA cleavage at matrix attachment sites. J. Biol. Chem. 270:1995a;18685-18690.
18. Gromova I. I., Thomsen B., Razin S. V. Different topoisomerase II antitumor drugs direct similar specific long-range fragmentation of an amplified c-MYC gene locus in living cells and in high-salt-extracted nuclei. Proc. Natl Acad. Sci. USA. 92:1995b;102-106.
19. Hertzberg R. P., Caranfa M. J., Hecht S. M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry. 28:1989;4629-4638.
20. Hertzberg R. P., Busby R. W., Caranfa M. J., Holden K. G., Johnson R. K., Hecht S. M., Kingsbury W. D. Irreversible trapping of the DNA-topoisomerase I covalent complex. Affinity labeling of the camptothecin binding site. J. Biol. Chem. 265:1990;19287-19295.
21. Holm C., Goto T., Wang J. C., Botstein D. DNA topoisomerase II is required at the time of mitosis in yeast. Cell. 41:1985;553-563.
22. Iarovaia O., Hancock R., Lagarkova M., Miassod R., Razin S. V. Mapping of genomic DNA loop organization in a 500-kilobase region of the Drosophila X chromosome by the topoisomerase II-mediated DNA loop excision protocol. Mol. Cell. Biol. 16:1996;302-308.
23. Käs E., Laemmli U. K. In vivo topoisomerase II cleavage of the Drosophila histone and satellite III repeats: DNA sequence and structural characteristics. EMBO J. 11:1992;705-716.
24. Kawada S., Yamashita Y., Fujii N., Nakano H. Induction of a heat-stable topoisomerase II-DNA cleavable complex by nonintercalative terpenoides, terpentecin and clerocidin. Cancer Res. 51:1991;2922-2925.
25. Liu L. F., Wang J. C. Supercoiling of the DNA template during transcription. Proc. Natl Acad. Sci. USA. 84:1987;7024-7027.
26. Poljak L., Käs E. Resolving the role of topoisomerase II in chromatin structure and function. Trends Cell Biol. 5:1995;348-354.
27. Pommier Y. DNA topoisomerase II inhibitors. Teicher B. A. Cancer Therapeutics: Experimental and Clinical Agents. 1997;153-174 Humana Press, Totowa.
28. Pommier Y., Orr A., Kohn K. W., Riou J. F. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene. Cancer Res. 52:1992;3125-3130.
29. Pommier Y., Kohn K. W., Capranico G., Taxel C. Base sequence selectivity of topoisomerase inhibitors suggests a common model for drug action. Andoh T., Ikeda H., Oguro M. Molecular Biology of DNA Topoisomerases and Its Application to Chemotherapy. 1993;215-227 CRC Press, Boca Raton.
30. Pommier Y., Kohlhagen G., Kohn K. W., Leteurtre F., Wani M. C., Wall M. E. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc. Natl Acad. Sci. USA. 92:1995;8861-8865.
31. Redinbo M. R., Stewart L., Kuhn P., Champoux J. J., Hol W. G. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science. 279:1998;1504-1513.
32. Reitman M., Felsenfeld G. Developmental regulation of topoisomerase II sites and DNase I-hypersensitive sites in the chicken beta-globin locus. Mol. Cell. Biol. 10:1990;2774-2786.
33. Rowe T. C., Wang J. C., Liu L. F. In vivo localization of DNA topoisomerase II cleavage sites on Drosophila heat shock chromatin. Mol. Cell. Biol. 6:1986;985-992.
34. Sambrook J., Fritsch E. F., Maniatis T. Molecular Cloning: A Laboratory Manual. 1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
35. Shen L. L., Kohlbrenner W. E., Weigl D., Baranowski J. Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes. J. Biol. Chem. 264:1989;2973-2978.
36. Sun X., Wahlstrom J., Karpen G. Molecular structure of a functional Drosophila centromere. Cell. 91:1997;1007-1019.
37. Swedlow J. R., Sedat J. W., Agard D. A. Multiple chromosomal populations of topoisomerase II detected in vivo by time-lapse, three-dimensional wide-field microscopy. Cell. 73:1993;97-108.
38. Udvardy A., Schedl P. Chromatin structure, not DNA sequence specificity, is the primary determinant of topoisomerase II sites of action in vivo. Mol. Cell. Biol. 11:1991;4973-4984.
39. Udvardy A., Schedl P. The dynamics of chromatin condensation: redistribution of topoisomerase II in the 87A7 heat shock locus during induction and recovery. Mol. Cell. Biol. 13:1993;7522-7530.
40. Udvardy A., Schedi P., Sander M., Hsieh T. S. Novel partitioning of DNA cleavage sites for Drosophila topoisomerase II. Cell. 40:1985;933-941.
41. Varga-Weisz P. D., Wilm M., Bonte E., Dumas K., Mann M., Becker P. B. Chromatin-remodelling factor CHRAC contains the ATPases ISWI and topoisomerase II. Nature. 388:1997;598-602.
42. Wang J. C. DNA topoisomerases. Annu. Rev. Biochem. 65:1996;635-692.
43. Watt P. M., Louis E. J., Borts R. H., Hickson I. D. Sgs1: a eukaryotic homolog of E. coli RecQ that interacts with topoisomerase II in vivo and is required for faithful chromosome segregation. Cell. 81:1995;253-260.
44. Watt P. M., Hickson I. D., Borts R. H., Louis E. J. SGS1, a homologue of the Bloom's and Werner's syndrome genes, is required for maintenance of genome stability in Saccharomyces cerevisiae. Genetics. 144:1996;935-945.
45. Williams B. C., Murphy T. D., Goldberg M. L., Karpen G. H. Neocentromere activity of structurally acentric mini-chromosomes in Drosophila. Nature Genet. 18:1998;30-37.
46. Yang L., Rowe T. C., Nelson E. M., Liu L. F. In vivo mapping of DNA topoisomerase II-specific cleavage sites on SV40 chromatin. Cell. 41:1985;127-132.